

Corporate Presentation for 2023



KUANGLI BIO-TECH
HOLDINGS

Kuangli Bio-tech Holdings Co., Ltd

(Original Name: Kuangli Photoelectric Technology Co., Ltd.)

Stock Symbol : 6431

Disclaimer



KUANGLI BIO-TECH
HOLDINGS

- The forward-looking information presented in this presentation and related disclosures, including operational outlook, financial condition, and business forecasts, are based on internal data and information derived from the overall economic development situation, as of the time of this disclosure.
- The actual operational results, financial condition, and business performance of the company in the future may differ from the forward-looking information presented. Various factors, including but not limited to changes in market demand, policies and regulations, overall economic conditions, and other risks beyond the company's control, could contribute to such differences.
- The information provided in this presentation reflects the company's views as of the present moment regarding the future. It is neither expressly nor implicitly stated or guaranteed to be accurate, complete, or reliable. The company is not responsible for updating or revising the content of the presentation for any changes or adjustments that may occur in the future.



KUANGLI BIO-TECH
HOLDINGS

光麗生技控股股份有限公司

The content of the briefing

1 Company
Profile

2 Business
in China

3 Financial
Information

4 New business
in Taiwan

5 Q&A




KUANGLI BIO-TECH
HOLDINGS

光麗生技控股股份有限公司

1. Company Profile

The historical capital and revenue data of Kuangli Bio-tech Group over the years.



The Chronicle of Kuangli Bio-tech Group



KUANGLI BIO-TECH HOLDINGS

Photoelectric period

Restructuring period

Post-restructuring period

2002
-2012

- Kunshan Kuangli Optoelectronic Technology Co., Ltd. was established in May 2002
- Xinguangtai Optoelectronic Technology Co., Ltd. was established in December 2005
- Nuowei Optoelectronic Technology Co., Ltd. was established in August 2009.

2013

- In May 2013, the group structure was reorganized, with Cayman Kuangli Optoelectronic Technology Co., Ltd. established as the ultimate parent company.

2014

- In July 2014, Taizhou Kuangli Optoelectronic Technology Co., Ltd. was established.
- In December 2014, Kuangli Optoelectronic Technology Co., Ltd. was listed on the Taiwan Stock Exchange.

2019

- In May 2019, an investment was made in Alliance Capital Investment INC.
- In September 2019, all shares of Taizhou Kuangli Technology Co., Ltd. were sold.


2021

- In January 2021, a cash capital increase was carried out with the issuance of 4,800,000 common shares.
- In June 2021, the majority stake in ACIM was acquired.
- In June 2021, a private placement of 728,000 common shares was conducted.
- In October 2021, the 100% equity of Kunshan Xinguangtai Optoelectronic Technology Co., Ltd. was sold.
- In October 2021, the 49% equity of Kunshan Kuangli Optoelectronic Technology Co., Ltd. was sold.
- In November 2021, Kuangli Optoelectronic Technology Co., Ltd. officially changed its name to Kuangli Bio-tech Holdings Co., Ltd.

2022 - 2023

- In January 2022, the complete equity of ACIM was acquired.
- In February 2022, a private placement of 11,330,000 Class A Preferred Shares and 6,068,000 common shares was conducted.
- In June 2022, the business classification changed from "Optoelectronics Industry" to "Biotechnology Industry."
- In July 2022, the 51% equity of Kunshan Kuangli Optoelectronic Technology Co., Ltd. was sold.
- In June 2023, Yi dai in Shanghai established a new facility covering an area of 31,000 square meters.
- In 2023, Kuangli Bio-tech Holdings Group launched a new Healthcare integration brand platform called G CLINIC.

The current business structure of the Kuangli Bio-tech Group



Consumer bio-tech and Healthcare bio-tech



KUANGLI BIO-TECH
HOLDINGS

光麗生技控股股份有限公司

2. Business in China



Development of new products and technologies

Professor Hong Weizhang, former director of the Institute of Cosmetic Science and Technology of Jianan University of Pharmacology, was recruited as the vice president of R&D, and the establishment of the R&D center was expanded.

The new plant was completed

At present, the new plant has been completed and put into operation in June 2023, and the production capacity is expected to increase by 2-3 times.

Development of new customers and cutting-edge customers

Strive for the development of new customers and cutting-edge customers, New customers in 2023 include new customers such as Mi Zhu, Da Fu Yan, Dr.JE, Proton and Zhen Gege.


Development of pet care related products

In view of the huge pet-related market in China, pet owners have developed pet-related products, including pet toiletries and ear cleansers.

Shanghai Yi Dai Company Profile




KUANGLI BIO-TECH
HOLDINGS




Yi Dai Major Clients 2021-2023(1-9) Revenue

Unit: RMB (thousand) yuan




Shanghai Yi Dai -Percentage of Revenue Portfolio

2023年1~9月營收組合 佔比




2022年度1~12營收組合 佔比



■ 化妝水 ■ 面膜 ■ 潤膚膏及護膚乳液 ■ 洗護髮 ■ 混合類 ■ 其他

2021年度1~12營收組合 佔比



■ 化妝水 ■ 面膜 ■ 潤膚膏及護膚乳液 ■ 洗護髮 ■ 混合類 ■ 其他

■ 化妝水 ■ 潤膚膏及護膚乳液 ■ 混合類 ■ 面膜 ■ 洗護髮 ■ 其他




KUANGLI BIO-TECH
HOLDINGS

光麗生技控股股份有限公司

3. Financial Information (Consolidated)

Consolidated Revenue , Gross Profit & Net Income

Kuangli and Subsidiaries 2021/1-12, 2022/1-12, 2023/1-9 單位：新台幣仟元



註1：目前報表科目係還原停業單位損益表達。

註2：光麗集團自2021/6累積取得ACIM51%股權，故將ACIM集團營收及財務報表自2021/6起，納入合併編製，2022/1取得剩下49%累積取得ACIM100%股權。

重要財務比率

NT\$ Thousand	2021.12.31	2022.12.31	2023.09.30
Current Ratio	159.40%	146.63%	116.41%
Debt Ratio	40.56%	39.69%	45.03%
Debt-To-Equity Ratio	68.24%	65.82%	81.90%
Net Asset Value	9.42	9.81	8.83
EPS	0.51	(1.22)	(1.19)

註:

截至2023年9月30日，本公司業主權益為新台幣693,641仟元；普通股為57,239仟股；特別股為11,330仟股；每股淨值為新台幣8.83元。



KUANGLI BIO-TECH
HOLDINGS

光麗生技控股股份有限公司

4. New business in Taiwan



打造國際級最強大的智慧醫療平台

Smart G CLINIC Platform

G CARE



- 品牌建置行銷
- 個人化健康管理
- 診所聯盟系統整合
- 運動處方平台

G SMART



- 智慧雲端數據系統開發
- 遠距醫療平台

G FUTURE



- 個人化細胞產品研發
- 血漿產品研發
- 幹細胞分泌因子研發

G POWER

G CLINIC is a new Healthcare integration brand platform created by Taiwan Kuangli Group, focusing on addressing current gaps and challenges in healthcare that have not yet been fully addressed. The platform aims to develop customized personal healthcare solutions, with a focus on Healthcare integration, smart healthcare, clinic brand management, regenerative medicine, and specialized treatments in five major areas.

Healthcare integration

Smart Healthcare

Brand management

Regenerative medicine

Featured treatments

Brand Healthcare Clinic Service Areas

G CLINIC

- Smart Healthcare
- International Marketing
- Brand Licensing

Healthcare Channels

- Executing Healthcare
- Safety First
- Implementing the Brand

Business Scale
Education System
Brand Strength

Disease Treatment
Preventive Medicine
Healthcare Systems

Confidence Aesthetics
Self-Pay System
Customer Service



GCLINIC Target market positioning

Brand Positioning

G CLINIC Crafting a world-class personalized healthcare journey

To provide personalized and dedicated Healthcare services and health management for each customer, creating a precise healthcare experience. Emphasizing high quality, individual privacy, and the value of leading in health.

Target market

Integrated Healthcare clinic targeting the middle to high-end market.

Focusing on personalized custom healthcare and integrating smart technology.



Target audience

Successful Professionals Group - Individuals aged between 35 and 55, occupying middle to senior-level positions. The group comprises both genders equally and consists of professionals with stable income and a solid social standing, including corporate executives, entrepreneurs, and business leaders, among other accomplished individuals.

Health-conscious Middle-Aged Group - Individuals aged between 40 and 60, with an equal distribution of men and women. They prioritize health and anti-aging, considering their well-being as their wealth.

Brand Establishment



KUANGLI BIO-TECH
HOLDINGS



G CLINIC GROW YOUR LIFE

G meaning—
GLOBAL
GLAMOUR
GOOD LIFE (QUALITY)

延續現有年輕有活力的品牌印象並加入大膽挑戰三大的精神
曜意涵-曜，耀也，光明照耀也日出有曜



Clinic Brand




Smart Device Brand



Healthcare Product Brand




Building the ultimate intelligent healthcare platform for patients.



G Manage Data Centers




KUANGLI BIO-TECH
HOLDINGS



Taiwan Kuangli 2023/1-11 Revenue

Unit: NT\$1,000

Note: Includes monthly fixed rent income from May



Thank You
Q&A